|Title||Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitation (WARFARIN)|
A medication prescribed for prevention of cardiovascular events such as heart attack and stroke, Warfarin is the most commonly prescribed oral anticoagulant. The WARFARIN study is sponsored by Iverson Genetic Diagnostics, Inc. and involves the collection and analysis of blood samples. Genetic components can influence a patient's tolerance of Warfarin. Information gathered in this study will help researchers determine patients' optimal Warfarin dose, based on certain genes. Potential benefits from this study include helping scientists gain a better understanding of how genes influence drug effectiveness. For more information on the Warfarin Study, click here.
Subjects must be at least 65 years of age, beginning Warfarin and have a target INR of >2. For more information, visit the Cardiovascular Research site.
|Principal Name||J. Antonio G. Lopez, MD|
|Contact Name||Jamie Duffy, CCRC|
|Current Trial Type||Randomized, double blind, placebo-controlled|